NCT05481528View on ClinicalTrials.gov

A Study to Learn How Safe the Study Treatment Elinzanetant is and How it Moves Into, Through and Out of the Body When Given as Single Increasing Doses That Are Higher Than Normally Used Compared to Placebo and Moxifloxacin in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

August 19, 2022

Primary Completion Date

February 7, 2023

Study Completion Date

April 28, 2023

Conditions
Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and MenHot FlashesHealthy Volunteers
Interventions
DRUG

Moxifloxacin

Single oral dose of 400 mg moxifloxacin

DRUG

Elinzanetant (BAY3427080)

Single oral dose of elinzanetant

DRUG

Placebo

Single oral dose of placebo

Trial Locations (1)

89231

NUVISAN GmbH Neu-Ulm, Neu-Ulm

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT05481528 - A Study to Learn How Safe the Study Treatment Elinzanetant is and How it Moves Into, Through and Out of the Body When Given as Single Increasing Doses That Are Higher Than Normally Used Compared to Placebo and Moxifloxacin in Healthy Participants | Biotech Hunter | Biotech Hunter